{
    "nct_id": "NCT00898807",
    "title": "A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2014-06-26",
    "description_brief": "The purpose of this study is to evaluate the safety and efficacy of citalopram for agitation in Alzheimer's dementia.",
    "description_detailed": "This study is designed to examine the efficacy and safety of citalopram as treatment for clinically significant agitation in Alzheimer's dementia (AD) patients. It will also investigate pharmacogenomic, genetic, and clinical predictors of response to citalopram therapy. The management of agitation is a major priority in treating patients with AD. Non-pharmacologic options have limited effectiveness. Several pharmacologic options have been explored, but findings for anticonvulsants, antipsychotics, and cholinesterase inhibitors are disappointing or associated with questionable risk-benefit ratio. Better pharmacologic options are needed. Selective serotonin reuptake inhibitors (SSRIs) show promise as a treatment for agitation in AD, based on evidence of a link between agitation and brain serotonin system abnormalities in AD patients, and on preliminary clinical data from a single-site, randomized controlled trial (RCT) in which citalopram was superior to perphenazine and placebo.",
    "phase": [
        "PHASE3"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "recruitmentDetails": "Recruitment activities included chart review, telephone interviews and screens, discussion with physicians, and recruitment in the clinic waiting areas and assisted living facilities affiliated with the clinics. The recruitment period lasted from August 2009 to December 2012.",
            "groups": [
                {
                    "id": "FG000",
                    "title": "Citalopram and Psychosocial Intervention",
                    "description": "Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention\n\ncitalopram : target dose 30mg daily for 9 weeks"
                },
                {
                    "id": "FG001",
                    "title": "Placebo and Psychosocial Intervention",
                    "description": "Matching placebo, oral, and psychosocial intervention\n\nplacebo : daily for 9 weeks"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "94"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "92"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "86"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "83"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "8"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "9"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "5"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "3"
                                }
                            ]
                        },
                        {
                            "type": "Family pressure to discontinue",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "2"
                                }
                            ]
                        },
                        {
                            "type": "Lost to Follow-up",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "3"
                                }
                            ]
                        },
                        {
                            "type": "Death",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "1"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Citalopram and Psychosocial Intervention",
                    "description": "Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention\n\ncitalopram : target dose 30mg daily for 9 weeks"
                },
                {
                    "id": "BG001",
                    "title": "Placebo and Psychosocial Intervention",
                    "description": "Matching placebo, oral, and psychosocial intervention\n\nplacebo : daily for 9 weeks"
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "94"
                        },
                        {
                            "groupId": "BG001",
                            "value": "92"
                        },
                        {
                            "groupId": "BG002",
                            "value": "186"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Categorical",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "<=18 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Between 18 and 65 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "7"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "13"
                                        }
                                    ]
                                },
                                {
                                    "title": ">=65 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "88"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "85"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "173"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "78",
                                            "spread": "9"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "79",
                                            "spread": "8"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "78",
                                            "spread": "8"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "44"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "41"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "85"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "50"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "51"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "101"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Region of Enrollment",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "classes": [
                        {
                            "title": "United States",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "82"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "79"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "161"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Canada",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "12"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "13"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "25"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "NeuroBehavior Rating Scale-- Agitation",
                    "description": "NeuroBehavioral Rating Scale- Agitation(NBRS-A) assesses multiple types of psychopathology common in dementia and is based on a seven point Likert scale of increasing severity for each item(i.e., 0=not present, 1=very mild, 2-mild, 3=moderate, 4=moderately severe, 5=severe, 6=extremely severe). The NBRS agitation subscore includes NBRS 'inhibition', 'agitation', and 'hostility'. The range is 0 to 18 points. Higher scores indicate more symptoms.",
                    "populationDescription": "The primary analysis was an intention-to-treat analysis; analysis was conducted \"as randomized\". Data from the 186 randomized participants were used in the analytic model. 167 of the 186 patients had week 9 data on the NBRS.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "9 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Citalopram and Psychosocial Intervention",
                            "description": "Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention\n\ncitalopram : target dose 30mg daily for 9 weeks"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo and Psychosocial Intervention",
                            "description": "Matching placebo, oral, and psychosocial intervention\n\nplacebo : daily for 9 weeks"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "90"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "85"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "4.33",
                                            "spread": "0.31"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "5.26",
                                            "spread": "0.31"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Primary assessment of efficacy was based on intention-to-treat comparison of the difference in the NBRS-A scores at week 9 and comparison at week 9 for the CGIC. For the NBRS-A, the study was designed to have 85% power to detect a standardized difference at week 9 of 40% for citalopram compared to placebo at week 9.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.036",
                            "pValueComment": "P-value was not adjusted for multiple comparisons. All p-values are two-sided and p\\<0.05 was the threshold for statistical significance.",
                            "statisticalMethod": "Mixed Models Analysis",
                            "statisticalComment": "Mixed effects model w/ random intercept for patient, visit indicator, treatment by visit interactions and adjusted for baseline NBRS-A \\& cognition.",
                            "paramType": "Mean Difference (Net)",
                            "paramValue": "-0.93",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-1.80",
                            "ciUpperLimit": "-0.06",
                            "estimateComment": "Negative numbers favor citalopram group."
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change in Agitation(CGIC)",
                    "description": "Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change in agitation(CGIC) accesses clinically significant change in agitation. A trained clinician, blind to treatment assignment, uses a 7-point Likert scale to rate change of each patient along a continuum from \"marked improvement\"(1), \"no change\"(4), and \"marked worsening\"(7). A number of aspects of the agitation is considered such as emotional agitation, mood liability/distress, psychomotor agitation, verbal aggression, and physical aggression. Range is 1-7.",
                    "populationDescription": "The primary analysis was an intention-to-treat analysis; analysis was conducted \"as randomized\". Data from the 186 randomized participants were used in the analytic model. 167 of the 186 patients had week 9 data on CGIC.",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "percentage moderate/marked improvement",
                    "timeFrame": "Baseline to 9 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Citalopram and Psychosocial Intervention",
                            "description": "Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention\n\ncitalopram : target dose 30mg daily for 9 weeks"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo and Psychosocial Intervention",
                            "description": "Matching placebo, oral, and psychosocial intervention\n\nplacebo : daily for 9 weeks"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "86"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "81"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "40"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "26"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Primary assessment of efficacy was based on intention-to-treat comparison of the difference in the NBRS-A scores at week 9 and comparison at week 9 for the CGIC. For the CGIC proportional odds analysis, the study was designed to have power greater than 80% to detect a difference of 20% between citalopram and placebo in the proportions of patients who improve (or worsen).",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.007",
                            "pValueComment": "All p-values are two-sided and p \\<0.05 was the threshold for statistical significance. No adjustments were made for multiple comparisons.",
                            "statisticalMethod": "Proportional odds",
                            "statisticalComment": "estimated treatment effect from the proportional odds model",
                            "paramType": "Odds Ratio (OR)",
                            "paramValue": "2.13",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "1.23",
                            "ciUpperLimit": "3.69",
                            "estimateComment": "Positive numbers favors citalopram."
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Cohen-Mansfield Agitation Inventory (CMAI)",
                    "description": "CMAI examines several agitated behaviors including verbal, physical agitation, and other behaviors. Sub-items are summed. Range is 14-70. Higher scores indicate more severe symptoms.",
                    "populationDescription": "The primary analysis was an intention-to-treat analysis; analysis was conducted \"as randomized\". Data from the 186 randomized participants were used in the analytic model. 169 of the 186 patients had week 9 data.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "9 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Citalopram and Psychosocial Intervention",
                            "description": "Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention\n\ncitalopram : target dose 30mg daily for 9 weeks"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo and Psychosocial Intervention",
                            "description": "Matching placebo, oral, and psychosocial intervention\n\nplacebo : daily for 9 weeks"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "90"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "85"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "27.7",
                                            "spread": "6.7"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "28.7",
                                            "spread": "6.7"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Neuropsychiatric Inventory (NPI)-- Agitation Subscore",
                    "description": "NPI agitation score is based on responses from an informed caregiver involved in the patient's life. Symptom severity (1=mild, 2=moderate, 3=severe) is multiplied by frequency (1=occasionally, less than once/week; 4 = very frequently, once or more/day or continuously) to obtain the NPI agitation score.Range is 0-12. Higher scores indicate more severe symptoms.",
                    "populationDescription": "The primary analysis was an intention-to-treat analysis; analysis was conducted \"as randomized\". Data from the 186 randomized participants were used in the analytic model. 169 of the 186 patients had week 9 data.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "9 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Citalopram and Psychosocial Intervention",
                            "description": "Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention\n\ncitalopram : target dose 30mg daily for 9 weeks"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo and Psychosocial Intervention",
                            "description": "Matching placebo, oral, and psychosocial intervention\n\nplacebo : daily for 9 weeks"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "90"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "85"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "7.8",
                                            "spread": "2.2"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "8.0",
                                            "spread": "2.4"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "1",
            "description": "Adverse events (AEs) are collected systematically on the follow-up visit form; therefore, numbers of participants at risk for AEs reflect at least on follow-up visit form completed. Serious adverse events are often self-reported and can be collected any time throughout the study.",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Citalopram and Psychosocial Intervention",
                    "description": "Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention\n\ncitalopram : target dose 30mg daily for 9 weeks",
                    "seriousNumAffected": 8,
                    "seriousNumAtRisk": 94,
                    "otherNumAffected": 90,
                    "otherNumAtRisk": 90
                },
                {
                    "id": "EG001",
                    "title": "Placebo and Psychosocial Intervention",
                    "description": "Matching placebo, oral, and psychosocial intervention\n\nplacebo : daily for 9 weeks",
                    "seriousNumAffected": 7,
                    "seriousNumAtRisk": 92,
                    "otherNumAffected": 86,
                    "otherNumAtRisk": 86
                }
            ],
            "seriousEvents": [
                {
                    "term": "Mental status change",
                    "organSystem": "Psychiatric disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 94
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 92
                        }
                    ]
                },
                {
                    "term": "Sepsis",
                    "organSystem": "Infections and infestations",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 94
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 92
                        }
                    ]
                },
                {
                    "term": "Pneumonia",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 94
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 92
                        }
                    ]
                },
                {
                    "term": "Increased agitation",
                    "organSystem": "Psychiatric disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 94
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 92
                        }
                    ]
                },
                {
                    "term": "Fall",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 94
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 92
                        }
                    ]
                },
                {
                    "term": "Hypotension",
                    "organSystem": "Cardiac disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 94
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 92
                        }
                    ]
                },
                {
                    "term": "Chest pain",
                    "organSystem": "Cardiac disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 94
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 92
                        }
                    ]
                },
                {
                    "term": "Surgical removal of infected plate in wrist",
                    "organSystem": "Infections and infestations",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 94
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 92
                        }
                    ]
                },
                {
                    "term": "Lung cancer",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 94
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 92
                        }
                    ]
                },
                {
                    "term": "Abdominal pain",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 94
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 92
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Sweating",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 9,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 12,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Tremor",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 23,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 16,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Dizziness",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 22,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 19,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Gait instability",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 50,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 44,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Yawning",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 11,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 17,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Falls",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 15,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 10,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Headache",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 21,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 18,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Visual disturbance",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 12,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 14,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Somnolence",
                    "organSystem": "Psychiatric disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 47,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 42,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Insomnia",
                    "organSystem": "Psychiatric disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 28,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 39,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Anxiety",
                    "organSystem": "Psychiatric disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 65,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 66,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Deceased libido",
                    "organSystem": "Psychiatric disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 14,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 18,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Confusion",
                    "organSystem": "Psychiatric disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 69,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 72,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Suicidal thoughts",
                    "organSystem": "Psychiatric disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 6,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 4,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Abdominal pain",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 14,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 19,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Anorexia",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 40,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 26,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Nausea",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 5,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 6,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Diarrhea",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 25,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 12,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Dry mouth",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 21,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 24,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Indigestion",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 23,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 18,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Constipation",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 13,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 22,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Vomiting",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 5,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Asthenia",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 29,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 30,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Muscle pain",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 29,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 34,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Joint pain",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 40,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 48,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Ejaculatory dysfunction",
                    "organSystem": "Reproductive system and breast disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 6,
                            "numAtRisk": 48
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 3,
                            "numAtRisk": 48
                        }
                    ]
                },
                {
                    "term": "Upper respiratory infection",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 17,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 9,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Rhinitis",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 33,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 30,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Pneumonia",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Cough",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 27,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 26,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Bronchitis",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Nasal congestion",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 22,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 22,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Sore throat",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 7,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 7,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Fatigue",
                    "organSystem": "General disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 54,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 53,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Fever",
                    "organSystem": "Infections and infestations",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 9,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 86
                        }
                    ]
                },
                {
                    "term": "Drug allergy",
                    "organSystem": "General disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 4,
                            "numAtRisk": 90
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 4,
                            "numAtRisk": 86
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictiveAgreement": false
            },
            "pointOfContact": {
                "title": "Anne Casper",
                "organization": "Johns Hopkins",
                "email": "ashankl1@jhu.edu",
                "phone": "410-955-8183"
            }
        }
    },
    "target_category": "neuropsychiatric symptom improvement",
    "drug": [
        "Citalopram (Celexa) \u2014 selective serotonin reuptake inhibitor (SSRI), small-molecule antidepressant"
    ],
    "placebo": [
        "Matching placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests citalopram for agitation in Alzheimer dementia \u2014 this is treating a neuropsychiatric/behavioral symptom (agitation), not attempting to modify core AD pathology. Citalopram is an SSRI (small-molecule antidepressant). \ue200cite\ue202turn0search0\ue202turn1search0\ue201",
        "Act: Key extracted details \u2014 intervention: citalopram (target dose up to 30 mg/day in the CitAD trial) vs placebo in a randomized, double-blind, multicenter trial for agitation in probable AD; trial showed reduced agitation and caregiver distress but noted cognitive decline and QT prolongation as adverse effects. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Reflect: Classification check \u2014 because the drug is an SSRI small molecule used to reduce agitation (a behavioral/neuropsychiatric symptom) rather than to target amyloid/tau or to enhance cognition directly, the appropriate category is 'neuropsychiatric symptom improvement'. This aligns with the trial objective and published CitAD results. \ue200cite\ue202turn0search0\ue201",
        "Web-search evidence (selected results used to support the above): (1) CitAD randomized clinical trial reporting citalopram reduced agitation but had cognitive and cardiac (QT) adverse effects. \ue200cite\ue202turn0search0\ue201 (2) Design/methods paper describing the multicenter randomized placebo-controlled CitAD study. \ue200cite\ue202turn0search1\ue202turn0search6\ue201 (3) FDA information describing citalopram (Celexa) as an SSRI small-molecule antidepressant and safety communications about dose-related QT prolongation. \ue200cite\ue202turn1search0\ue202turn1search2\ue201 (4) Celexa prescribing information summarizing indications, dosing limits, and safety. \ue200cite\ue202turn1search3\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The intervention is citalopram, a selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter (SERT) and increases serotonergic neurotransmission \u2014 i.e., it acts on a neurotransmitter system rather than on amyloid, tau, inflammation, or other AD core pathologies. \ue200cite\ue202turn2search3\ue202turn2search6\ue201",
        "Act: Key extracted trial details \u2014 the CitAD study was a randomized, double\u2011blind, placebo\u2011controlled multicenter trial of citalopram (planned titration to 30 mg/day) for agitation in probable Alzheimer disease; it found reduced agitation and caregiver distress but also showed modest cognitive worsening and dose\u2011dependent QT interval prolongation. These facts show the drug was used to treat a neuropsychiatric/behavioral symptom via serotonergic modulation, not to modify core AD biology. \ue200cite\ue202turn0search4\ue202turn1search1\ue202turn1search2\ue201",
        "Reflect: Classification check \u2014 because the mechanism is modulation of the serotonin neurotransmitter system (SERT/5\u2011HT) and the trial goal was symptomatic reduction of agitation (a neuropsychiatric symptom) rather than disease modification, the most specific CADRO category is D) Neurotransmitter Receptors. If one emphasized the clinical aim (neuropsychiatric symptom improvement) that describes the trial purpose, but CADRO maps the molecular/physiologic target (serotonergic neurotransmission) to category D. \ue200cite\ue202turn2search3\ue202turn1search1\ue201",
        "Web-search evidence (selected sources used): (1) FDA safety communication on citalopram (QT prolongation, dose limits). \ue200cite\ue202turn0search0\ue202turn0search1\ue201 (2) CitAD trial design and methods. \ue200cite\ue202turn0search4\ue201 (3) CitAD randomized trial results (reduced agitation, cognitive worsening, QT prolongation) \u2014 JAMA / PMC article. \ue200cite\ue202turn1search1\ue202turn1search0\ue201 (4) Mechanism summaries noting citalopram/SSRIs inhibit serotonin reuptake via SERT. \ue200cite\ue202turn2search3\ue202turn2search6\ue201"
    ]
}